Florzolotau - APRINOIA Therapeutics
Alternative Names: 1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol; 18F-APN-1607; 18F-PM-PBB3; [18F]-APN-1607([18F]-PM-PBB3); APN-1607; Florzolotau 18FLatest Information Update: 28 Jun 2024
At a glance
- Originator APRINOIA Therapeutics
- Developer APRINOIA Therapeutics; Chang Gung Memorial Hospital; Nanjing Medical University; National Institute of Radiological Sciences
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Alzheimer's disease
- Phase II Progressive supranuclear palsy
- No development reported Corticobasal degeneration; Tauopathies
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Progressive-supranuclear-palsy(Diagnosis, In the elderly, In volunteers, In adults) in USA (IV)
- 20 May 2024 Aprinoia plans to initiate a phase III trial for Progressive Supranuclear Palsy in USA, United Kingdom, Europe and Asia
- 08 May 2024 Florzolotau - APRINOIA Therapeutics receives Fast Track designation for Progressive supranuclear palsy [IV] (Diagnosis, In the elderly, In volunteers, In adults) in USA